Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002144-33
    Sponsor's Protocol Code Number:RLM-MD-04
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2018-11-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-002144-33
    A.3Full title of the trial
    A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Estudio de fase 3, aleatorizado, en doble ciego y controlado con placebo, de 52 semanas de duración, para evaluar la seguridad y la eficacia de relamorelina en pacientes con gastroparesia diabética.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A 52-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Estudio de 52 semanas de duración, para evaluar la seguridad y la eficacia de relamorelina en pacientes con gastroparesia diabética.
    A.3.2Name or abbreviated title of the trial where available
    Diabetic Gastroparesis Study 4
    A.4.1Sponsor's protocol code numberRLM-MD-04
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAllergan Ltd.
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAllergan Ltd.
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAllergan Ltd.
    B.5.2Functional name of contact pointNick Connolly
    B.5.3 Address:
    B.5.3.1Street AddressMarlow, International, Parkway
    B.5.3.2Town/ cityMarlow
    B.5.3.3Post codeSL7 1YL
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+44(0)1628 494387
    B.5.5Fax number+44(0)1628 494887
    B.5.6E-mailConnolly_Nick@allergan.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRelamorelin
    D.3.2Product code RM-131
    D.3.4Pharmaceutical form Solution for injection in pre-filled pen
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRELAMORELIN
    D.3.9.1CAS number 661472-41-9
    D.3.9.2Current sponsor codeRM-131
    D.3.9.3Other descriptive nameInp-DBal-DTrp-Phe-Apc-NH2
    D.3.9.4EV Substance CodeSUB182309
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection in pre-filled pen
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Diabetic Gastroparesis
    gastroparesia diabética.
    E.1.1.1Medical condition in easily understood language
    Diabetic Gastroparesis
    gastroparesia diabética.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10051153
    E.1.2Term Diabetic gastroparesis
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To compare the efficacy of relamorelin with that of placebo in participants with DG with respect to: DGSSS, Individual symptoms of DGSSS (Nausea, Abdominal pain, Postprandial fullness, Bloating), Vomiting Frequency
    Comparar la eficacia de la relamorelina frente a la del placebo en participantes con gastroparesia diabética en cuanto a:
    -Puntuación de la Intensidad de los Síntomas de Gastroparesia Diabética (Diabetic Gastroparesis Symptom Severity Score, DGSSS)
    -Síntomas individuales de la DGSSS: Náuseas, Dolor abdominal, Plenitud posprandial, Meteorismo
    Frecuencia de los vómitos
    E.2.2Secondary objectives of the trial
    - To compare the safety of relamorelin with that of placebo in participants with DG
    Comparar la seguridad de la relamorelina frente a la del placebo en participantes con gastroparesia diabética
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Rollover Participants:
    Participants who were not randomization-eligible at the end of the Run-in Period of lead-in Studies RLM-MD-01 or RLM-MD-02 are eligible to be randomized in the study if all of the following criteria apply:
    In the lead-in studies, participants must have met all Screening Visit and Run-in Period criteria for randomization into the Treatment Period (including compliance with dosing, entry of diary data into the DGSSD) except that:
    1. They had zero vomiting episodes and an average daily DGSSS of ≥ 12 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device;
    OR
    2. They had vomiting episodes and an average daily DGSSS of ≥ 12 but < 16 at the end of the lead-in study Run-in Period, as reported using the electronic hand-held device.

    De Novo Participants
    Participants who undergo screening and run-in procedures for Study RLM MD-04 are eligible to be included in the study if all of the following criteria apply:
    1. Male or female participants aged 18 years or older at Screening (Visit –2)
    2. T1DM or T2DM of at least 5 years’ duration, with controlled and stable blood glucose levels (ie, no episodes of diabetic ketoacidosis, Hyperosmolar Hyperglycemic Nonketotic Diabetic Syndrome, or severe hypoglycemia within the 6 months preceding Screening [Visit –2])
    3. HbA1c ≤ 11.0% at Screening (Visit –2) in participants being treated with oral and/or parenteral medications for T1DM or T2DM with the goal of achieving controlled and stable glucose levels
    4. DG defined as at least a 3-month history prior to Screening (Visit –2) of symptoms (one of which must be nausea) on an ongoing basis that are suggestive of GP (eg, nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety)
    5. Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and Follow-up Period
    A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization, not breastfeeding, and at least one of the following conditions applies:
    a. Not a woman of childbearing potential (WOCBP)
    OR
    b. A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 7 days after the last dose of study treatment
    6. Documentation of absence of an obstructing lesion on upper endoscopy or other equivalent diagnostic test, performed at some time before Screening (Visit –2) but after the appearance of symptoms that led to the diagnosis of DG
    7. Nausea and/or at most a single episode of vomiting during the 2 weeks prior to Screening (Visit –2), as ascertained by participant history
    8. Delayed GE confirmed by abnormal GEBT, defined as GE half-time (t½) ≥ 79 minutes at the start of the placebo-controlled Run-in Period (Visit 2 of RLM-MD-01, RLM-MD-02, or this study). In countries where the GEBT is not available, delayed GE may be confirmed by abnormal scintigraphy result (> 60% retention at 2 hours or > 10% at 4 hours)
    9. BMI > 18.5 kg/m2
    10. Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study procedures
    Additional inclusion criteria for randomization after the 2-week, placebo Run-in Period:
    11. Compliance with the entry of data into the hand-held electronic device on at least 10 of 14 days during the Run-in Period
    12. Compliance with administration of SC twice daily injections, as evidenced by entries made by the participant using the electronic, hand-held device on at least 10 of 14 days during the Run-in Period
    13. The average of the daily DGSSS from the 2-week, Run-in Period must be ≥ 12
    6.1.1. Participantes que continúan desde el estudio anterior (rollover participants)
    Se podrá aleatorizar en este estudio a los participantes que no fueron elegibles para la aleatorización al final del Periodo de Preinclusión de los estudios iniciales RLM-MD-01 o RLM-MD-02, siempre que se cumplan todos los criterios siguientes:
    En los estudios iniciales, los participantes deben haber cumplido todos los criterios de la Visita de Selección y del Periodo de Preinclusión para la aleatorización en el Periodo de Tratamiento (lo que incluye el cumplimiento del tratamiento y la entrada de datos en el Diario de la Intensidad de los Síntomas de Gastroparesia Diabética [DGSSD]) salvo que:
    1. No tuvieron episodios de vómitos y presentaron un promedio de la Puntuación de la Intensidad de los Síntomas de Gastroparesia Diabética (DGSSS) diaria >/= 12 al final del Periodo de Preinclusión del estudio inicial, según el registro mediante el dispositivo electrónico de bolsillo;
    O BIEN
    2. Tuvieron episodios de vómitos y presentaron un promedio de la DGSSS diaria >/= 12 y < 16 al final del Periodo de Preinclusión del estudio inicial, según el registro mediante el dispositivo electrónico de bolsillo.

    6.1.2. Participantes nuevos
    Los participantes que se sometan a los procedimientos de selección y preinclusión en el estudio RLM-MD-04 serán elegibles para entrar en el presente estudio siempre que se cumplan todos los criterios siguientes:
    1. Participantes de ambos sexos con una edad igual o superior a 18 años en la Selección (Visita 2)
    2. Diabetes mellitus de tipo 1 o de tipo 2 desde hace al menos 5 años, con niveles estables y controlados de glucemia (es decir, sin episodios de cetoacidosis diabética, síndrome diabético hiperosmolar hiperglucémico no cetósico ni hipoglucemia severa en los 6 meses anteriores a la Selección [Visita 2])
    3. HbA1c ≤11,0% en la Selección (Visita 2) en los participantes tratados con antidiabéticos orales y/o parenterales por diabetes mellitus de tipo 1 o de tipo 2 con el objetivo de alcanzar niveles controlados y estables de glucemia
    4. Gastroparesia diabética, definida como un cuadro en curso de síntomas indicativos de gastroparesia (por ejemplo, náuseas, dolor abdominal, plenitud posprandial, meteorismo, vómitos y saciedad precoz), uno de los cuales debe ser náuseas, desde como mínimo 3 meses antes de la Selección (Visita 2)
    5. Mujeres dispuestas a reducir en lo posible el riesgo de embarazo durante todo el estudio clínico y el Periodo de Seguimiento
    Podrán participar las mujeres que no estén embarazadas (resultado negativo de una prueba de embarazo en orina antes de la aleatorización; véase el Apéndice 5), no practiquen la lactancia natural y cumplan alguna de las siguientes condiciones:
    a. No ser potencialmente fértiles, según se define en el Apéndice 5
    O BIEN
    b. Si son potencialmente fértiles, estar dispuestas a seguir las normas sobre anticoncepción indicadas en el Apéndice 5 durante el Periodo de Tratamiento y por lo menos los 7 días siguientes a la última administración del tratamiento del estudio
    6. Ausencia de una lesión obstructiva confirmada mediante endoscopia alta u otra prueba diagnóstica equivalente, realizada antes de la Selección (Visita 2), pero después de la aparición de los síntomas que llevaron al diagnóstico de gastroparesia diabética
    7. Náuseas y/o a lo sumo un solo episodio de vómito en las 2 semanas previas a la Selección (Visita 2), según consta en la historia del participante
    8. Vaciamiento gástrico retardado, confirmado mediante una prueba de aliento de vaciamiento gástrico con resultado anormal, definido como semitiempo (t½) de vaciamiento gástrico >/= 79 minutos al comienzo del Periodo de Preinclusión controlado con placebo (Visita 2 de los estudios RLM-MD-01 o RLM-MD-02, o de este estudio). En los países donde no se disponga de la prueba de aliento de vaciamiento gástrico, este parámetro podrá confirmarse mediante gammagrafía con resultado anormal (retención >60% a las 2 horas o >10% a las 4 horas). Véase el Manual de Referencia del Estudio
    9. Índice de masa corporal > 18,5 kg/m2
    10. Con capacidad de otorgar su consentimiento informado por escrito antes de los procedimientos del estudio y con capacidad y voluntad de cumplir los procedimientos del estudio

    Criterios de inclusión adicionales para la aleatorización tras el Periodo de Preinclusión con placebo de 2 semanas:
    11. Cumplimiento de la introducción de datos en el dispositivo electrónico de bolsillo durante por lo menos 10 de los 14 días del Periodo de Preinclusión
    12. Cumplimiento del tratamiento con las inyecciones subcutáneas administradas dos veces al día, a juzgar por las entradas efectuadas por el participante mediante el dispositivo electrónico de bolsillo durante por lo menos 10 de los 14 días del Periodo de Preinclusión
    13. El promedio de la DGSSS diaria en el Periodo de Preinclusión de 2 semanas debe ser >/=12
    E.4Principal exclusion criteria
    Rollover Participants
    Participants will be excluded from this study if any of the lead-in study exclusion criteria apply at Screening (Visit 1) and at the end of the Run-in Period (Visit 3) for randomization into the Treatment Period of Studies RLM MD 01 and RLM MD-02, except as specified in the inclusion criteria
    De Novo Participants
    1. Symptomatic Irritable Bowel Syndrome at Screening (Visit –2)
    2. Small intestinal bacterial overgrowth (SIBO) at Screening (Visit –2)
    3. History of anorexia nervosa, binge-eating, bulimia, or other eating disorder within 5 years of Screening (Visit –2)
    4. History of intestinal malabsorption (including celiac disease even if well-controlled on a gluten-free diet) or pancreatic exocrine insufficiency; also, history of non-celiac gluten sensitivity
    5. History of belching disorders, other nausea and vomiting disorders (eg, chronic nausea and vomiting syndrome, cyclic vomiting syndrome, cannabinoid hyperemesis syndrome), or rumination syndrome
    6. History of chronic obstructive pulmonary disease or other causes of pulmonary dysfunction that have resulted in CO2 retention
    7. Gastric or duodenal ulcer within 3 months of Screening (Visit 1)
    8. Evidence of hepatic disease defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x ULN, and/or direct bilirubin ≥ 2 x ULN at Screening (Visit 2)
    9. History of malignancy in the 3 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
    10. Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
    11. Use of metoclopramide, domperidone, prucalopride, macrolide antibiotics (eg, erythromycin, clarithromycin, azithromycin), or other drugs considered to be GI pro-motility agents for at least 10 days prior to the start of the Run-in Period (Visit –1)
    12. Positive results on the urine drug screen will exclude participants from participating in the study. The significance of a positive screen result for drugs prescribed for the participant (eg, barbiturates, benzodiazepines, amphetamines, but not cannabinoids) should be assessed by the Investigator as to whether their stable-dose usage is clinically appropriate, and, therefore, should not be exclusionary; use of these drugs on an as-needed basis is not allowed
    13. Currently taking opiates, or expecting to use opiates during the course of the clinical study.
    14. Treatment with glucagon-like peptide-1 (GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period (Visit –1)
    15. History of pyloric injection of botulinum toxin within 6 months of screening
    16. History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure (a history of diagnostic endoscopy is not exclusionary)
    17. Randomization in any previous study in which relamorelin was a treatment
    18. Estimated glomerular filtration rate (eGFR) of < 30 mL/min
    19. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study
    20. Allergic to, or intolerant of egg, wheat, milk, or algae, as these are components of the GEBT study meal
    21. Females who are pregnant, nursing, or planning a pregnancy during the study
    22. The participant has a condition or is in a situation which, in the investigator’s opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant’s participation in the study
    23. Participant is directly or indirectly involved in the conduct and administration of this study as an investigator, subinvestigator, study coordinator, other study staff member, or employee of Allergan, Inc.; or the participant is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study; or the participant is enrolled in this study at another clinical study site
    24. Functional dyspepsia diagnosed before the diagnosis of diabetes mellitus
    6.2.1. Participantes que continúan desde el estudio anterior (rollover participants)
    Se excluirá de este estudio a los participantes que cumplan cualquiera de los criterios de exclusión del estudio inicial en la Selección (Visita 1) y al final del Periodo de Preinclusión (Visita 3) para la aleatorización en el Periodo de Tratamiento de los estudios RLM-MD-01 o RLM-MD-02, excepto según se señala en los criterios de inclusión (Sección
    6.1).

    6.2.2. Participantes nuevos
    1. Síndrome del intestino irritable sintomático en la Selección (Visita 2)
    2. Proliferación bacteriana en el intestino delgado en la Selección (Visita 2)
    3. Antecedentes de anorexia nerviosa, sobreingesta compulsiva, bulimia u otro trastorno alimentario en el plazo de los 5 años anteriores a la Selección (Visita 2)
    4. Antecedentes de malabsorción intestinal (incluida la celiaquía, aunque esté bien controlada con una dieta sin gluten), de insuficiencia pancreática exocrina o de sensibilidad al gluten no celiaca
    5. Antecedentes de trastornos de eructación, otros trastornos de náuseas y vómitos (por ejemplo, síndrome de náuseas y vómitos crónicos, síndrome de vómitos cíclicos, síndrome de hiperemesis por canabinoides) o síndrome de rumiación
    6. Antecedentes de enfermedad pulmonar obstructiva crónica u otras causas de disfunción pulmonar que hayan dado lugar a retención de CO2
    7. Úlcera gástrica o duodenal en el plazo de los 3 meses anteriores a la Selección (Visita 1)
    8. Signos de hepatopatía consistentes en valores de alanina-aminotransferasa (ALT) o aspartato-aminotransferasa (AST) ≥3 veces el límite superior de la normalidad y/o bilirrubina directa ≥2 veces el límite superior de la normalidad la Selección (Visita 2)
    9. Antecedentes de neoplasias malignas en los 3 años previos a la Visita 1, excepto el cáncer cutáneo basocelular o espinocelular o el carcinoma de cuello uterino in situ, adecuadamente tratados
    10. Nutrición parenteral o presencia de sonda nasogástrica o enteral para alimentación o descompresión, en la actualidad
    11. Administración de metoclopramida, domperidona, prucaloprida, antibióticos macrólidos (por ejemplo, eritromicina, claritromicina, azitromicina) u otros medicamentos con actividad procinética (Tabla 7 2) durante como mínimo 10 días antes del comienzo del Periodo de Preinclusión (Visita 1)
    12. Resultados positivos en el análisis de sustancias en orina, lo que será motivo de exclusión de la participación en el estudio. El Investigador deberá valorar la importancia de los resultados positivos de sustancias en orina en relación con los medicamentos prescritos al participante (por ejemplo, barbitúricos, benzodiacepinas o anfetaminas, pero no canabinoides) para constatar si el uso de una dosis estable por el participante es clínicamente adecuado y, por tanto, no constituye motivo de exclusión; no se permite el uso de estos fármacos según necesidad
    13. Administración de opiáceos, actual o prevista durante el periodo del estudio clínico (véase una excepción a esta prohibición en la Sección 7.7.1)
    14. Tratamiento con agonistas del péptido glucagonoide 1 (GLP 1) durante como mínimo 6 semanas antes del comienzo del Periodo de Preinclusión (Visita 1)
    15. Antecedentes de inyección pilórica de toxina botulínica en el plazo de los 6 meses anteriores a la Selección
    16. Antecedentes de cirugía gástrica, por ejemplo, fundoplicatura, gastrectomía, colocación de un marcapasos gástrico, vagotomía o intervención bariátrica (los antecedentes de endoscopia diagnóstica no son motivo de exclusión)
    17. Aleatorización en cualquier estudio anterior que incluyera relamorelina
    18. Tasa de filtración glomerular estimada < 30 ml/min
    19. Participación en un estudio de medicamentos o productos sanitarios en investigación, en la actualidad o en el plazo de los 30 días anteriores a la entrada en este estudio
    20. Alergia o intolerancia al huevo, al trigo, a la leche o a las algas, ya que forman parte de la comida para la prueba de aliento de vaciamiento gástrico
    21. Mujeres embarazadas, en periodo de lactancia o que tengan previsto quedarse embarazadas durante el estudio. Véase información sobre las mujeres potencialmente fértiles en el Apéndice 5
    22. Enfermedad o situación del participante que, en opinión del investigador, le supondría un riesgo importante, confundiría los resultados del estudio o dificultaría de manera considerable su participación en el estudio
    23. Participante que interviene directa o indirectamente en el desarrollo o la administración de este estudio como investigador, subinvestigador, coordinador del estudio, otro miembro del personal del estudio o empleado de Allergan, Inc.; o participante que es familiar de primer grado, pareja o pariente que reside con alguna de las personas mencionadas, intervinientes de forma directa o indirecta en el estudio; o participante que ha entrado en este estudio en otro centro del estudio clínico
    24. Dispepsia funcional diagnosticada antes que la diabetes mellitus
    E.5 End points
    E.5.1Primary end point(s)
    - DGSSS Week 12 Responder
    - Vomiting Frequency Week 12 Responder
    - DGSSS Week 52 Responder
    - Vomiting Frequency Week 52 Responder
    - Nausea Week 12 Responder
    - Abdominal Pain Week 12 Responder
    - Bloating Week 12 Responder
    - Postprandial Fullness Week 12 Responder
    - Change from baseline to Week 52 in average weekly DGSSS
    - Change from baseline to Week 52 in average weekly number of vomiting episodes
    Paciente con Respuesta (Responder) en cuanto a la DGSSS en la Semana 12
    Paciente con Respuesta en cuanto a la Frecuencia de los Vómitos en la Semana 12
    Paciente con Respuesta en cuanto a la DGSSS en la Semana 52
    Paciente con Respuesta en cuanto a la Frecuencia de los Vómitos en la Semana 52
    Paciente con Respuesta en cuanto a las Náuseas en la Semana 12
    Paciente con Respuesta en cuanto al Dolor Abdominal en la Semana 12
    Paciente con Respuesta en cuanto al Meteorismo en la Semana 12
    Paciente con Respuesta en cuanto a la Plenitud Posprandial en la Semana 12
    Variación respecto al valor Basal del promedio semanal de la DGSSS en la Semana 52
    Variación respecto al valor Basal del promedio semanal del número de episodios de vómitos en la Semana 52
    E.5.1.1Timepoint(s) of evaluation of this end point
    - week 12
    - week 52
    -semana 12
    -semana 52
    E.5.2Secondary end point(s)
    - Adverse events (AEs), clinical laboratory values, vital signs, electrocardiograms (ECGs), hemoglobin A1c (HbA1c), and anti-relamorelin antibodies
    Acontecimientos adversos (Adverse event, AE), valores de laboratorio, constantes vitales, electrocardiogramas (ECG), hemoglobina A1c (HbA1c) y anticuerpos antirrelamorelina
    E.5.2.1Timepoint(s) of evaluation of this end point
    The whole study duration
    Durante todo el estudio.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA174
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belgium
    Brazil
    Bulgaria
    Colombia
    Denmark
    France
    Germany
    Hungary
    India
    Israel
    Italy
    Korea, Republic of
    Latvia
    Malaysia
    Mexico
    Philippines
    Poland
    Romania
    Russian Federation
    Saudi Arabia
    Singapore
    South Africa
    Spain
    Taiwan
    Thailand
    Ukraine
    United Arab Emirates
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit of the last participant in the study.
    El fin del estudio se define como la fecha de la última visita del último paciente del studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days25
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days25
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 450
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state14
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 328
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who complete the study should follow up with the investigator regarding treatment at the end of the study.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Clinical Research Network, UK
    G.4.3.4Network Country United Kingdom
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-01-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-12-03
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2020-11-05
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 01:46:37 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA